What to look out for at ESMO 2019

esmo_2019_big

This year, the annual congress of the European Society for Medical Oncology (ESMO) is taking place in Barcelona, Spain.

With the World Conference on Lung Cancer having wrapped up at the same venue just a couple of weeks ago, many conference delegates will no doubt have been tempted to schedule a late summer holiday in the city, rather than travel back and forth to attend both.

Those who are in attendance face a plethora of data to digest, with particular highlights in breast, ovarian, head and neck, lung and other cancers, spread over 280 sessions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical